DC therapy after low-dose chemotherapy

Fumiaki Tanaka, Hiroshi Yamaguchi, Mitsuhiko Ota, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

Abstract

DC therapy is now considered to be one of the weapons with which to fight against a variety of cancers. We have investigated the in vivo antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) following low-dose chemotherapy. Combination of i.t. injection of DC and systemic chemotherapy induced antitumor effects on not only the DC-treated tumor but also on a distant tumor inoculated in the contralateral flank of the animal. To analyze the mechanisms of the systemic antitumor effect induced in this system, we analyzed the cytolytic activity against tumors including injected tumors and others. The cytolytic activity of effector cells from the treated animals was tumor-specific, and was mainly restricted to CD 8 and MHC class I (p<0.01). This study suggests that the strategy of i.t. injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the near future.

Original languageEnglish
Pages (from-to)9-14
Number of pages6
JournalBiotherapy
Volume17
Issue number1
Publication statusPublished - Jan 1 2003

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'DC therapy after low-dose chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Tanaka, F., Yamaguchi, H., Ota, M., Inoue, H., & Mori, M. (2003). DC therapy after low-dose chemotherapy. Biotherapy, 17(1), 9-14.